Drugs / H5N1 IIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05397119 Background | Jul 2022 → Oct 2023 | influenza | BlueWillow Biologics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5N1 IIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397119 ↗ |
| Modality | Vaccine | “licensed H5N1 IIV IM vaccine” NCT05397119 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05397119 ↗ |